Core Viewpoint - A class action lawsuit has been filed against Klarna Group plc for failing to disclose material financial risks during its IPO, impacting investors who purchased securities between September 7, 2025, and December 22, 2025 [1][3]. Company Overview - Klarna Group plc, headquartered in Sweden, provides Buy Now, Pay Later (BNPL) solutions, facilitating loans for small retail transactions between consumers and merchants [2]. Legal Allegations - The lawsuit claims that Klarna's IPO documents did not adequately disclose significant financial risks, particularly the potential for a sharp increase in loss reserves due to the high-risk profiles of its customer base [3]. - It is alleged that many customers were experiencing financial hardships and were unsophisticated, increasing the likelihood of defaulting on loans [3]. Market Reaction - Following a report on November 18, 2025, indicating that Klarna had set aside more provisions for credit losses than the market anticipated, the company's share price fell by 21%, closing at $31.31, down from the IPO price of $40 [4].

Group 1 - A class action lawsuit has been filed against Fermi Inc. for allegedly misleading investors about tenant demand and funding status for its Project Matador campus during the Class Period from October 1, 2025, to December 11, 2025 [1] - The lawsuit claims that Fermi did not disclose the reliance on a single tenant's funding commitment for construction financing, which posed significant risks [1] - Following the termination of a $150 million funding agreement by the first tenant on December 12, 2025, Fermi's shares dropped by nearly 34%, closing at $10.09 per share [1] Group 2 - Fermi Inc. is headquartered in Amarillo, Texas, and aims to establish a network of large, grid-independent data centers powered by various energy sources, including nuclear and solar [1] - The company's flagship project, Project Matador, is intended to be the world's largest private energy campus dedicated to AI data centers [1] - Berger Montague, the law firm representing the investors, has a strong track record in complex litigation and has recovered over $50 billion for clients over its 55 years of operation [1]

Group 1 - A class action lawsuit has been filed against Masonite International Corporation on behalf of investors who sold Masonite common stock during the period from June 5, 2023, through February 8, 2024 [1][2]. - The lawsuit alleges that Masonite failed to disclose multiple formal acquisition offers from Owens Corning at significant premiums while the company was repurchasing its own shares [3]. - Upon Masonite's acquisition by Owens Corning, investors learned that shares had been repurchased at artificially depressed prices, leading to damages for investors during the Class Period [4]. Group 2 - Investors who sold Masonite securities during the Class Period have until April 7, 2026, to seek appointment as lead plaintiff representatives [2]. - Masonite is headquartered in Tampa, Florida, and is a global designer and producer of interior and exterior doors for both residential and non-residential building industries [2].

PHILADELPHIA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against Varonis Systems, Inc. (NASDAQ: VRNS) (“Varonis” or the “Company”) on behalf of investors who purchased or otherwise acquired Varonis securities during the period of February 4, 2025 through October 28, 2025 (the “Class Period”). Investor Deadline: Investors who purchased Varonis securities during the Class Period may, no later than March 9, 2026, seek ...

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for allegedly misleading investors regarding the effectiveness of its gene therapy candidate AMT-130 and the likelihood of FDA approval [1][3]. Company Overview - uniQure, based in Amsterdam, specializes in developing and commercializing gene therapies for severe diseases, particularly focusing on Huntington's disease and other neurological disorders [2]. Legal Proceedings - The lawsuit pertains to investors who acquired uniQure securities between September 24, 2025, and October 31, 2025, with a deadline of April 13, 2026, for potential lead plaintiff appointments [2]. - The complaint claims that uniQure misrepresented the effectiveness of AMT-130 and the status of FDA agreement on study endpoints, which led to a significant stock price increase of nearly 250% from $13.66 to $47.50 per share shortly after the misleading statements [3]. Stock Performance - Following the revelation on November 3, 2025, that the FDA agreement on study design was not finalized, uniQure's stock plummeted over 49%, dropping from $67.69 to $34.29 per share [4].

Core Viewpoint - A class action lawsuit has been filed against Kyndryl Holdings, Inc. for allegedly making false statements and failing to disclose material weaknesses in internal controls, leading to significant investor losses when the truth emerged [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Kyndryl securities from August 7, 2024, to February 9, 2026 [1]. - Investors have until April 13, 2026, to seek appointment as lead plaintiff representatives [2]. - The complaint alleges that Kyndryl's financial statements were materially misstated and that the company lacked adequate internal controls [3]. Group 2: Impact on Investors - On February 9, 2026, Kyndryl's shares fell by 55% following the revelation of material weaknesses in internal controls and an SEC investigation into cash management practices [4]. - Investors suffered heavy losses as a result of the decline in share value [4]. Group 3: Company Overview - Kyndryl is headquartered in New York and provides IT infrastructure services to enterprise customers globally [2].

Core Viewpoint - A class action lawsuit has been filed against Ramaco Resources, Inc. on behalf of investors who purchased its securities during the specified class period, alleging misleading information regarding the company's mining operations [1][3]. Group 1: Lawsuit Details - The lawsuit claims that a report by Wolfpack Research on October 23, 2025, labeled Ramaco's Brook Mine as a "hoax" and a "Potemkin Mine," asserting that no significant mining activity had occurred since its groundbreaking in July 2025 [3]. - Following the publication of the report, Ramaco's stock price dropped by $3.81, nearly 10%, closing at $36.01 per share, with unusually high trading volume [3]. Group 2: Company Background - Ramaco Resources, Inc. is headquartered in Lexington, Kentucky, and focuses on coal and natural resources, developing mining operations and mineral projects in the United States [2].

Core Viewpoint - A class action lawsuit has been filed against Coupang, Inc. for allegedly making false statements regarding its cybersecurity and regulatory compliance during the specified Class Period from May 7, 2025, to December 16, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Coupang failed to disclose critical information about its cybersecurity measures, which allegedly exposed the company to a heightened risk of data breaches [3]. - Investors became aware of the true state of Coupang's cybersecurity through revelations starting in November 2025, which indicated that a former employee had access to sensitive customer information for nearly six months without detection [4]. Group 2: Investor Information - Investors who purchased Coupang securities during the Class Period have until February 17, 2026, to seek appointment as a lead plaintiff representative of the class [2]. - The lawsuit has implications for Coupang's stock price, which experienced significant declines following the disclosures about its cybersecurity issues [4].

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. on behalf of investors who acquired its securities during the specified class period, alleging misrepresentation and failure to disclose critical information regarding the company's drug development process [1][3]. Company Overview - uniQure N.V. is a biotechnology company based in Amsterdam, focusing on gene therapies for severe diseases, including Huntington's disease [2]. Legal Allegations - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study for the drug AMT-130 and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline due to the need for additional studies [3]. Stock Impact - Following the disclosure that the FDA did not agree with the use of Phase I/II data for BLA submission, uniQure's stock price plummeted over 49%, dropping from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against SLM Corporation (Sallie Mae) for allegedly misleading investors about loan delinquencies during a specific period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Sallie Mae securities from July 25, 2025, to August 14, 2025 [1][2]. - Investors have until February 17, 2026, to seek appointment as lead plaintiff representative [2]. Group 2: Allegations - The complaint alleges that Sallie Mae misrepresented the state of its loan delinquencies, claiming that rising early-stage delinquencies were typical seasonal trends while praising their loss mitigation strategies [3]. - Following the revelation of the true state of loan delinquencies, Sallie Mae's stock fell by $2.67 per share, or 8.09%, closing at $30.32 on August 15, 2025 [4].